Alaunos Therapeutics, Inc. – NASDAQ:TCRT
Alaunos Therapeutics stock price today
$2.24
+0.40
+21.74%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 3 hours
Alaunos Therapeutics stock price monthly change
+183.08%
month
Alaunos Therapeutics stock price quarterly change
+183.08%
quarter
Alaunos Therapeutics stock price yearly change
+3245.45%
year
Alaunos Therapeutics key metrics
Market Cap | 3.13M |
Enterprise value | 105.02M |
P/E | -3.37 |
EV/Sales | 35.94 |
EV/EBITDA | -3.30 |
Price/Sales | 42.63 |
Price/Book | 3.23 |
PEG ratio | -0.06 |
EPS | -1.68 |
Revenue | N/A |
EBITDA | -18.47M |
Income | -26.77M |
Revenue Q/Q | N/A |
Revenue Y/Y | -99.79% |
Profit margin | -1291.24% |
Oper. margin | -1201.4% |
Gross margin | 0% |
EBIT margin | -1201.4% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlaunos Therapeutics stock price history
Alaunos Therapeutics stock forecast
Alaunos Therapeutics financial statements
| Jun 2023 | 4K | -8.77M | -219325% |
|---|---|---|---|
| Sep 2023 | 0 | -8.47M | |
| Dec 2023 | 1K | -7.84M | -784300% |
| Mar 2024 | 1K | -1.68M | -168200% |
| Sep 2025 | 1K | -7.85M | -785234.1% |
|---|---|---|---|
| Oct 2025 | 1K | -7.85M | -785238.1% |
| Dec 2025 | 0 | -88.47M | |
| Dec 2025 | 1K | -5.90M | -590173.5% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 27927000 | 6.27M | 22.48% |
|---|---|---|---|
| Sep 2023 | 19440000 | 5.54M | 28.5% |
| Dec 2023 | 8263000 | 1.95M | 23.67% |
| Mar 2024 | 6037000 | 1.24M | 20.54% |
| Jun 2023 | -7.00M | -135K | -11.98M |
|---|---|---|---|
| Sep 2023 | -6.37M | 1K | 0 |
| Dec 2023 | -7.38M | 1.50M | 0 |
| Mar 2024 | -1.91M | 0 | 0 |
Alaunos Therapeutics alternative data
| Aug 2023 | 34 |
|---|---|
| Sep 2023 | 34 |
| Oct 2023 | 34 |
| Nov 2023 | 34 |
| Dec 2023 | 34 |
| Jan 2024 | 34 |
| Feb 2024 | 34 |
| Mar 2024 | 34 |
| Apr 2024 | 34 |
| May 2024 | 1 |
| Jun 2024 | 1 |
| Jul 2024 | 1 |
Alaunos Therapeutics other data
6.14%
-29.92%
of TCRT is owned by hedge funds
71
-48
13.32M
-64.22M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2022 | 2000000 | 0 |
| Sep 2023 | 0 | 68014 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BOYLE KEVIN S. SR. director, officer: Chief Execut.. | Common Stock | 68,014 | $0.14 | $9,522 | ||
Purchase | VIESER JAIME director | Common Stock | 1,250,000 | $0.65 | $812,500 | ||
Purchase | POSTMA ROBERT W director | Common Stock | 750,000 | $0.65 | $487,500 | ||
Sale | DE GROOT ELEANOR officer: EVP, Ope.. | Common Stock | 20,132 | $1.27 | $25,568 | ||
Purchase | BOYLE KEVIN S. SR. director, officer: Chief Execut.. | Common Stock | 9,116 | $1.4 | $12,762 | ||
Purchase | BOYLE KEVIN S. SR. director, officer: Chief Execut.. | Common Stock | 884 | $1.4 | $1,238 | ||
Purchase | VIESER JAIME director | Common Stock | 100,000 | $1.91 | $191,000 | ||
Purchase | POSTMA ROBERT W director | Common Stock | 54,492 | $1.73 | $94,271 | ||
Purchase | POSTMA ROBERT W director | Common Stock | 20,508 | $1.73 | $35,479 | ||
Purchase | HAGEN HEIDI director | Common Stock | 23,770 | $1.76 | $41,835 |
| Quarter | Transcript |
|---|---|
| Q1 2023 10 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 7 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 14 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 15 Aug 2022 | Q2 2022 Earnings Call Transcript |
-
What's the price of Alaunos Therapeutics stock today?
One share of Alaunos Therapeutics stock can currently be purchased for approximately $2.24.
-
When is Alaunos Therapeutics's next earnings date?
Unfortunately, Alaunos Therapeutics's (TCRT) next earnings date is currently unknown.
-
Does Alaunos Therapeutics pay dividends?
No, Alaunos Therapeutics does not pay dividends.
-
How much money does Alaunos Therapeutics make?
Alaunos Therapeutics has a market capitalization of 3.13M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 99.83% to 5K US dollars.
-
What is Alaunos Therapeutics's stock symbol?
Alaunos Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TCRT".
-
What is Alaunos Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Alaunos Therapeutics?
Shares of Alaunos Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Alaunos Therapeutics have?
As Jul 2024, Alaunos Therapeutics employs 1 workers, which is 97% less then previous quarter.
-
When Alaunos Therapeutics went public?
Alaunos Therapeutics, Inc. is publicly traded company for more then 20 years since IPO on 24 Aug 2005.
-
What is Alaunos Therapeutics's official website?
The official website for Alaunos Therapeutics is alaunos.com.
-
Where are Alaunos Therapeutics's headquarters?
Alaunos Therapeutics is headquartered at 8030 El Rio Street, Houston, TX.
-
How can i contact Alaunos Therapeutics?
Alaunos Therapeutics's mailing address is 8030 El Rio Street, Houston, TX and company can be reached via phone at +34 63554099.
Alaunos Therapeutics company profile:
Alaunos Therapeutics, Inc.
alaunos.comExchange:
NASDAQ
Full time employees:
1
Industry:
Biotechnology
Sector:
Healthcare
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
8030 El Rio Street
Houston, TX 77054
Houston, TX 77054
CIK: 0001107421
ISIN: US98973P2002
CUSIP: 98973P101
